155P Tarlatamab for patients with small cell lung cancer: 6-8 hour outpatient vs 48 hour inpatient monitoring in cycle 1
Year: 2024
Type: article
Abstract: Tarlatamab, a bispecific T-cell engager (BiTE®) immunotherapy targeting delta-like ligand 3, has shown promising outcomes in previously treated small cell lung cancer (SCLC). We evaluated the safety of a reduced 6-8 hour (h) monitoring period with tarlatamab in an outpatient setting in the phase 1 DeLLphi-300 study.
Source: Immuno-Oncology Technology
Authors: A.C. Chiang, M.E. Olmedo Garcia, J. Carlisle, A. Dowlati, N. Reguart, E. Felip, P.J. Jost, N. Steeghs, R. Stec, S. Gadgeel, H.H.F. Loong, W. Jiang, A. Hamidi, A. Parkes, L. Paz-Ares
Institutions: Yale University, Hospital Universitario Ramón y Cajal, Winship Cancer Institute, Case Western Reserve University, Hospital Clínic de Barcelona, Vall d'Hebron Hospital Universitari, Medical University of Graz, The Netherlands Cancer Institute, Medical University of Warsaw, Henry Ford Health, Henry Ford Hospital, Chinese University of Hong Kong, Prince of Wales Hospital, Amgen (United States), Hospital Universitario 12 De Octubre
Language: English
Topic: Lung Cancer Research Studies
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,170
Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, Gilead Sciences, Celgene, F. Hoffmann-La Roche, Regeneron Pharmaceuticals, Merck KGaA, Exelixis, Les Laboratories Pierre Fabre, Mirati Therapeutics, BeiGene, Incyte, Actuate Therapeutics, Seagen, Astellas Pharma, Sociedad Española de Oncología Médica, Servier, Ipsen, Grifols, Genentech, Takeda Pharmaceuticals International, Daiichi Sankyo Europe, Cilag
OpenAlex ID: W4405375175